Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
PLAVIX (clopidogrel) is an oral antiplatelet agent approved in 1997 that reduces thrombotic cardiovascular events by inhibiting platelet aggregation. It is widely used in acute coronary syndromes, percutaneous coronary intervention, and stroke prevention. The drug works as a prodrug that irreversibly blocks the P2Y12 ADP receptor on platelet surfaces.
As loss of exclusivity approaches, the brand team is likely consolidating around managed care, outcomes-based strategies, and differentiation initiatives rather than growth expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)
MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)
Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI
Worked on PLAVIX at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on PLAVIX offers stability in a mature, established franchise with deep institutional knowledge and strong customer relationships, but limited growth runway. Career progression may require transition to emerging markets, lifecycle extensions, or organizational pivot to newer cardiovascular assets.